Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 treating patients with multi-drug resistant cancers. Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets.
Cellestia awarded Innosuisse Grant to advance a groundbreaking Graft versus Host Disease prevention therapy…
The Investigator Initiated Phase II Trial at MD Anderson Cancer Center combining CB-103 and Venetoclax for the treatment of rr/r-T-ALL patients is now open for recruitment…
| Building | B2 |
|---|---|
| Industry | Biotech |
| Research Topics | autoimmune diseases & multi-drug resistant cancers |
| Employees | 7 |
| Founding year | 2014 |
Home 
About us 
Offer 
News 
